


### Background

VT-464 is an oral non-steroidal dual lyase-selective CYP17 Lyase inhibitor and a potent androgen receptor (AR) antagonist (Figure 1). VT-464 is being evaluated without steroid co-administration in multiple Phase 1 and 2 castration-resistant prostate cancer (CRPC) studies.

Figure 1 – VT-464 Structure and Dual Mechanism of Action



VT-464 inhibits the growth of multiple breast cancer cell lines *in vitro* including MCF7 (estrogen receptor (ER)(+)/AR low), tamoxifen-resistant MCF7, and MDA-MB-453 (ER(-) /AR(+)) in a dose-dependent manner and with greater potency/efficacy than enzalutamide (Ellison et al., 2015 [P3-14-04]). A subset of TNBC and most ER(+) breast cancers express AR, making them potential targets for VT-464 since it directly inhibits both androgen/estrogen synthesis and AR transcriptional activity.

The current study is an open-label, single arm, Ph 1/2 study of VT-464 in women with AR(+) triple negative (TNBC) or ER(+)/HER2 normal unresectable locally advanced or metastatic breast cancer (NCT#02580448).

### Study Objectives

#### Phase 1

##### Primary Objective

- Describe the dose-limiting adverse events and determination of the maximum-tolerated dose of VT-464 in women with unresectable locally advanced or metastatic breast cancer that is ER / progesterone receptor negative (PgR(-)) and HER2 normal (TNBC) or post-menopausal women with ER positive and HER2 normal breast cancer (ER(+) breast cancer)

#### Phase 1 (cont.)

##### Secondary Objectives

- Describe the pharmacokinetics of VT-464 in the ITT population
- Estimate efficacy of VT-464 as measured by clinical benefit rate at 16 weeks (CBR16) for patients with TNBC and clinical benefit rate at 24 weeks (CBR24) for patients with ER(+) breast cancer
- Estimate efficacy of VT-464 as measured by the overall response rate (ORR) based on RECIST 1.1
- Estimate efficacy of VT-464 as measured by progression-free survival (PFS)
- Describe the safety profile of VT-464

#### Phase 2

##### Primary Objective

- Determine the CBR16 for patients with androgen receptor (AR) positive TNBC and CBR24 for patients with ER(+) BC in their respective evaluable populations

##### Secondary Objectives

- Estimate efficacy of VT-464 as measured by PFS
- Estimate efficacy of VT-464 as measured by ORR based on RECIST 1.1
- Estimate CBR16 for patients in TNBC Cohort with AR  $\geq 1\%$
- Estimate CBR24 for patients in ER (+) Cohort with AR  $\geq 1\%$
- Describe the safety profile of VT-464
- Describe the pharmacokinetics of VT-464

#### Exploratory/ Correlative Objectives


- To determine the extent of AR expression and signaling in breast tissue and to evaluate the relationship of AR expression with VT-464 effects on circulating tumor biomarkers, circulating hormones and clinical outcomes.

### Study Design

#### Main Eligibility Criteria

- ER(+)  $\geq 1\%$  with HER2-normal breast cancer or AR(+)  $\geq 1\%$  TNBC
  - Evaluable TNBC patients for Phase 2 will have AR  $\geq 10\%$
- Postmenopausal or under ovarian suppression (ER(+)) patients
- Received at least 1 prior line of endocrine therapy (ER(+) patients)
- ECOG PS  $\leq 1$
- Unresectable locally advanced or metastatic breast cancer
- Available representative tumor specimen to enable correlative science

#### Study Schema



#### Phase 1

- 6 patients (either ER(+)/HER2-normal or AR(+) TNBC) enrolled per-cohort starting at 750 mg qd (the MTD for men with CRPC)
- 2 or more DLTs in the first 28-days of treatment will confirm that the next lower dose be examined in a new cohort
- A DLT is defined as a Grade 3 or greater, drug related (possibly or greater) adverse event within the first 28 days of dosing
- VT-464 given once-nightly with dinner in a continuous dosing schedule
- Six to 12 patients enrolled in Phase 1

#### Phase 2

- Parallel AR(+) TNBC and ER(+)/HER2-normal cohorts enrolled using MTD from Phase 1
- VT-464 given once-nightly with dinner in a continuous dosing schedule
- Simon's two-stage design with pre-determined futility parameters
- ~35 patients enrolled per cohort

#### Predictive Biomarker Evaluation Plan

- Identify predictive biomarkers of response/resistance to VT-464
- Assess if early changes in circulating biomarkers can predict response to VT-464 or impending disease progression in advance of traditional measures such as radiologic measurements and clinical symptoms
- Identify mechanisms of acquired resistance to VT-464 by rebiopsy of tumor tissue (if safe and feasible) and circulating biomarkers at the time of progression in patient who derive significant benefit from therapy
- Provide rationale for future combination studies
- Biomarkers will be evaluated from tumor biopsies, CTCs, ctDNA, endocrine panel and genomic DNA

### Site Activation and Accrual

Five of approximately 30 sites planned for activation have been initiated. The first patient was enrolled August 2015 and 6 patients have been enrolled to-date in Phase 1. Phase 2 is expected to be initiated in early 2016.